Moderna's trading volume on March 5th was $762 million, a 41.16% decrease compared to the previous trading day.

K-LinePoet · 2026-04-07T06:54:48+00:00

On March 5, 2026, biotechnology company Moderna (MRNA) had a trading volume of $762 million, ranking 191st among U.S. stocks that day. The trading volume decreased by 41.16% compared to the previous day, with a daily trading volume of 13.9064 million shares.Moderna (MRNA) closed at $53.83 on March 5, 2026, down 6.87%. The stock has increased by 4.10% over the past 5 trading days, gained 0.49% for the entire month of March, up 82.54% since the beginning of the year, and has risen 52.88% over the past 52 weeks.If the company has been listed for less than 52 weeks, the 52-week change is calculated from the listing date to the present (this also applies to companies listed for less than 1 month or fewer than 5 trading days).| Moderna (MRNA) | Trading Volume / USD | Change in Trading Volume from Yesterday | Trading Volume || --- | -

K-LinePoet

2026-04-07 06:54:48

On March 5, 2026, biotech company Moderna (MRNA) had trading volume of $762 million, ranking 191st among U.S. stocks that day. Trading volume decreased by 41.16% from the previous day, and the trading volume that day was 13.9064 million shares.

On March 5, 2026, Moderna (MRNA) fell 6.87%, to $53.83. Over the past five trading days, the stock rose 4.10%, the entire month of March rose 0.49%, year-to-date rose 82.54%, and over the past 52 weeks rose 52.88%.

*If the company has been listed for less than 52 weeks, the 52-week gain or loss is the gain or loss since listing (the same applies to cases where the listing time is less than 1 month or less than 5 trading days)

Moderna (MRNA)	Trading value/US dollars	Change in trading value from yesterday	Trading volume
March 5, 2026	762 million	-41.16%	13.9064 million
March 4, 2026	1.3B	178.08%	23.1036 million
March 3, 2026	466 million	-6.47%	9.2588 million
March 2, 2026	498 million	4.53%	9.4247 million
February 27, 2026	477 million	60.18%	9.0697 million

Moderna, Inc. was incorporated on July 22, 2016, under the laws of the State of Delaware. The company is a leader in messenger RNA (messenger RNA) medicine. Working for more than a decade at the intersection of science, technology, and health, the company has developed medicines at an unprecedented speed and efficiency, including one of the earliest and most effective COVID-19 vaccines. The company’s mRNA platform has made possible the development of therapies and vaccines for infectious diseases, immuno-oncology, rare diseases, and autoimmune diseases. With a unique culture and a global team driven by Moderna’s values and ways of thinking, the company aims to change the future of human health in a responsible manner and to deliver the greatest possible impact to people through mRNA medicines.

View Original

This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.